LSP 6 is the successor fund to our previous venture capital funds that we have raised over the past 30 years, and it is our largest fund to date. Through the years, we have committed to the same and proven investment strategy and focus. LSP 6, currently at €410 million, just like its predecessors, is investing in healthcare companies developing novel and ground-breaking new medicines and technologies that provide solutions to unmet medical needs. This strategy and focus has paved the way for LSP to become one of Europe’s foremost names in healthcare investing.
Over the years, we have supported the development of numerous companies, providing them with the capital required to grow and flourish. Typically, we adopt an active, hands-on approach to our investments. We work closely with portfolio company management teams, co-directors and major co-investors in an effort to achieve the long-term goals that we set together from the outset. Our investments are primarily located in Europe and occasionally in the US, and made at various stages of a company's development. Historically, we have made early investments in assets at the preclinical phase and formed companies around them. We also make later-stage investments requiring less intense guidance and support, but more capital. In addition, we have also made several investments in companies that were spun out from large pharmaceutical companies around assets that were no longer deemed of strategic interest to the parent companies. The LSP 6 fund targets to make up to 20 investments.